TPG ART leads Inocucor Technologies’ $39m Series B

The funds will help fund a new US headquarters, boost production at Inocucor's Montreal pilot production and R&D facility, and increase staff.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this